Brought to you by 
Galapagos licenses Phase II RA candidate to Abbott; AbbVie takes over and deal expands to Crohn's disease; deal ends
18 Dec 2015
Executive Summary
Galapagos NV has licensed Abbott Laboratories Inc. exclusive global rights to develop and commercialize GLPG0634, a highly selective Janus kinase (JAK) inhibitor in Phase II for rheumatoid arthritis and other autoimmune diseases.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Terminated
Deal Type
-
Alliance
- Co-Promotion
- Includes Contract
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com